Salotto KE, Olson Jr WC, Pollack KE, Illendula A, Michel E, Henriques S, Fox T, Walker S, Dunlap-Brown M, Slingluff Jr CL, Kester M, Snyder HW*. A nano-enhanced vaccine for metastatic melanoma immunotherapy. Cancer Drug Resist 2022;5: [Accept]. http://dx.doi.org/10.20517/cdr.2021.1323.
Qi X, Wu F, Kim SH, Kaifi JT, Kimchi ET, Snyder H, Illendula A, Fox T, Kester M, Staveley-O’Carroll, Kevin F, Li G*. Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer. FASEB Journal 2022 PMID: 3529407.
Doffo J, Bamopoulos SA, Orben F, Zang C, Dekker AT, Brouwer RW, Baluapuri A, Reichert M, lllendula A, Schick M, Wolf E, Wilfred FJ, Jcken E, Esposito I, Keller U, Schneider G, Wirth M *. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc. Natl. Acad. Sci. 2022, PMID: 35197278.
Yu H, Khokhlatchev AV, Chew C, Illendula A, Conaway M, Dryden K, Maeda DLNF, Rajasekaran V, Kester M, and Zeichner SL*. Minicells from highly genome reduced escherichia coli: Cytoplasmic and Surface Expression of Recombinant Proteins and Incorporation in the Minicells. ACS Synthetic Biology 2021 PMID: 34516078.
Rose JT, Boyd JR, Gordon JA, Kang M, Moskovitz E, Bouffard NA, Fritz AJ, Illendula A, Bushweller JH, Lian JB, Stein JL, Stein GS, Zaidi SK*. Mitotic gene bookmarking by RUNX1 contributes to stabilization of the normal mammary epithelial phenotype. Oncotarget 2020 PMID: 32655837
Alegre F, Ormonde AR, Godinez DR, Illendula A, Bushweller JH, Wittenburg LA*. The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma. Vet Comp Oncol 2020 PMID: 31381810.
Zhou N, Alvaro GU, Zheng XY, Vogl D, Garfall AL, Bernabei L, Saraf A, Florens L, Washburn MP, Illendula A, Bushweller JH, Busino L*. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. Leukemia 2019, 33(8):2006-2021. PubMed PMID: 30760870
8. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takasashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN*. RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood 2019, 34(1):59-73. PubMed PMID: 31023702.
Deltcheva E, Wray J, James C, Boiers C, Chettri JB, Richardson S, Illendula A, Bushweller JH, Nimmo R, Enver T*. Exploiting CBF dependency in B-acute lymphoblastic leukemia as a novel therapeutic approach Exp. Hematol 2019 doi: https://doi.org/10.1016/j.exphem.2019.06.348.
Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH*. CBFβ-SMMHC inhibition triggers apoptosis by disrupting MYC chromatin cynamics in acute myeloid leukemia. Cell. 2018, 174(1):172-186. PubMed PMID: 30142347.